Skip to main content
. 2019 Aug 14;9(21):6175–6190. doi: 10.7150/thno.35572

Figure 5.

Figure 5

QPCT could bind with HRAS and promote the stability of HRAS by reducing its ubiquitination degradation. (A) Co-immunoprecipitation of QPCT and HRAS in 786-O and A498 cells. (B) Immunofluorescence analysis of QPCT (red) and HRAS (green) in OS-RC-2 and 786-O cells. Scale bar, 10 μm. (C) Representative images of western blot analysis of QPCT and HRAS in QPCT-overexpressing and control 786-O and A498 cells. (D) Immunohistochemistry of QPCT and HRAS in xenografts. Scale bar, 100 μm. (E) Representative images of western blot analysis of QPCT and HRAS in ACHN and OS-RC-2 cells transfected with sh-QPCT or sh-NC. (F) Western blot analysis of HRAS in QPCT-overexpressing and control 786-O and A498 cells after cycloheximide (CHX) and sunitinib (5 μM) treatment for various times. (G) Western blot analysis of HRAS ubiquitination in QPCT-overexpressing and control 786-O and A498 cells after sunitinib (5 μM) treatment for 48 h. GAPDH was used as a loading control. Results are presented as the means ± SD. *p<0.05, **p<0.01.